Some of the challenges in drug development for irritable bowel syndrome.
Mayer
E A
EA
UCLA/CURE Neuroenteric Disease Program Departments of Medicine and Physiology UCLA School of Medicine, Los Angeles, CA 90024, USA. emayer@ucla.edu
D000818:Animals; D003109:Colonic Diseases, Functional / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000494:pharmacology*; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects; D009420:Nervous System / Q000187:drug effects; D015282:Octreotide / Q000494:pharmacology; D051381:Rats; D017481:Receptors, Somatostatin / Q000819:agonists
D005765:Gastrointestinal Agents; D017481:Receptors, Somatostatin; D015282:Octreotide